(VEEV) Veeva Systems - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US9224751084
Stock: Software, Data, Analytics, Consulting
Total Rating 37
Risk 95
Buy Signal -0.45
| Risk 5d forecast | |
|---|---|
| Volatility | 33.2% |
| Relative Tail Risk | -13.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.37 |
| Alpha | -33.19 |
| Character TTM | |
|---|---|
| Beta | 1.024 |
| Beta Downside | 0.327 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.83% |
| CAGR/Max DD | 0.05 |
EPS (Earnings per Share)
Revenue
Description: VEEV Veeva Systems March 04, 2026
Veeva Systems Inc. (VEEV) provides cloud-based software and services to the global life sciences industry. Its offerings span commercial, data, and development solutions. The companys business model focuses on recurring revenue from software subscriptions.
Veeva Commercial Cloud includes CRM, medical content management, promotional materials management, and analytics for pharmaceutical and biotechnology companies. Veeva Data Cloud offers customer reference data, deep industry data, and de-identified patient data. Veeva Development Cloud provides solutions for clinical trial execution, data management, safety, and regulatory information management. The company also offers Veeva Quality Cloud for life sciences and consumer products sectors, and business consulting services.
Veeva also provides professional services, including implementation, project management, solution design, and ongoing managed services. The life sciences industry has a high demand for specialized software due to complex regulatory requirements and extensive R&D processes.
For more detailed analysis, consider exploring ValueRays comprehensive reports.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 860.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 0.39 > 1.0 |
| NWC/Revenue: 200.2% < 20% (prev 172.8%; Δ 27.41% < -1%) |
| CFO/TA 0.17 > 3% & CFO 1.38b > Net Income 860.3m |
| Net Debt (-1.57b) to EBITDA (908.7m): -1.73 < 3 |
| Current Ratio: 7.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (168.0m) vs 12m ago 1.80% < -2% |
| Gross Margin: 75.67% > 18% (prev 0.74%; Δ 7493 % > 0.5%) |
| Asset Turnover: 42.34% > 50% (prev 41.17%; Δ 1.17% > 0%) |
| Interest Coverage Ratio: -3.26 > 6 (EBITDA TTM 908.7m / Interest Expense TTM -263.2m) |
Altman Z'' 10.00
| A: 0.76 (Total Current Assets 7.11b - Total Current Liabilities 944.9m) / Total Assets 8.10b |
| B: 0.51 (Retained Earnings 4.12b / Total Assets 8.10b) |
| C: 0.12 (EBIT TTM 858.9m / Avg Total Assets 7.28b) |
| D: 3.91 (Book Value of Equity 4.13b / Total Liabilities 1.06b) |
| Altman-Z'' Score: 11.55 = AAA |
Beneish M -3.09
| DSRI: 1.06 (Receivables 371.8m/301.3m, Revenue 3.08b/2.66b) |
| GMI: 0.98 (GM 75.67% / 73.93%) |
| AQI: 0.76 (AQ_t 0.10 / AQ_t-1 0.14) |
| SGI: 1.16 (Revenue 3.08b / 2.66b) |
| TATA: -0.06 (NI 860.3m - CFO 1.38b) / TA 8.10b) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of VEEV shares?
As of March 04, 2026, the stock is trading at USD 185.91 with a total of 2,238,692 shares traded.
Over the past week, the price has changed by +5.76%, over one month by -2.56%, over three months by -22.96% and over the past year by -15.09%.
Over the past week, the price has changed by +5.76%, over one month by -2.56%, over three months by -22.96% and over the past year by -15.09%.
Is VEEV a buy, sell or hold?
Veeva Systems has received a consensus analysts rating of 3.88.
Therefore, it is recommended to buy VEEV.
- StrongBuy: 12
- Buy: 7
- Hold: 11
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the VEEV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 293.1 | 57.7% |
| Analysts Target Price | 293.1 | 57.7% |
VEEV Fundamental Data Overview March 04, 2026
P/E Trailing = 35.3016
P/E Forward = 21.0526
P/S = 9.6833
P/B = 4.2495
P/EG = 0.8229
Revenue TTM = 3.08b USD
EBIT TTM = 858.9m USD
EBITDA TTM = 908.7m USD
Long Term Debt = 89.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.5m USD (from shortTermDebt, last quarter)
Debt = 89.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.57b USD (from netDebt column, last quarter)
Enterprise Value = 23.28b USD (29.83b + Debt 89.8m - CCE 6.64b)
Interest Coverage Ratio = -3.26 (Ebit TTM 858.9m / Interest Expense TTM -263.2m)
EV/FCF = 17.18x (Enterprise Value 23.28b / FCF TTM 1.35b)
FCF Yield = 5.82% (FCF TTM 1.35b / Enterprise Value 23.28b)
FCF Margin = 43.98% (FCF TTM 1.35b / Revenue TTM 3.08b)
Net Margin = 27.93% (Net Income TTM 860.3m / Revenue TTM 3.08b)
Gross Margin = 75.67% ((Revenue TTM 3.08b - Cost of Revenue TTM 749.5m) / Revenue TTM)
Gross Margin QoQ = 75.41% (prev 75.26%)
Tobins Q-Ratio = 2.88 (Enterprise Value 23.28b / Total Assets 8.10b)
Interest Expense / Debt = 33.69% (Interest Expense 30.2m / Debt 89.8m)
Taxrate = 24.48% (76.6m / 312.8m)
NOPAT = 648.6m (EBIT 858.9m * (1 - 24.48%))
Current Ratio = 7.53 (Total Current Assets 7.11b / Total Current Liabilities 944.9m)
Debt / Equity = 0.01 (Debt 89.8m / totalStockholderEquity, last quarter 7.04b)
Debt / EBITDA = -1.73 (Net Debt -1.57b / EBITDA 908.7m)
Debt / FCF = -1.16 (Net Debt -1.57b / FCF TTM 1.35b)
Total Stockholder Equity = 6.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.83% (Net Income 860.3m / Total Assets 8.10b)
RoE = 13.38% (Net Income TTM 860.3m / Total Stockholder Equity 6.43b)
RoCE = 13.17% (EBIT 858.9m / Capital Employed (Equity 6.43b + L.T.Debt 89.8m))
RoIC = 10.09% (NOPAT 648.6m / Invested Capital 6.43b)
WACC = 9.74% (E(29.83b)/V(29.92b) * Re(9.69%) + D(89.8m)/V(29.92b) * Rd(33.69%) * (1-Tc(0.24)))
Discount Rate = 9.69% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.27%
[DCF] Terminal Value 74.91% ; FCFF base≈1.23b ; Y1≈1.44b ; Y5≈2.17b
[DCF] Fair Price = 176.3 (EV 27.41b - Net Debt -1.57b = Equity 28.98b / Shares 164.4m; r=9.74% [WACC]; 5y FCF grow 17.99% → 2.90% )
EPS Correlation: 90.19 | EPS CAGR: 24.39% | SUE: 1.54 | # QB: 13
Revenue Correlation: 98.71 | Revenue CAGR: 14.67% | SUE: 1.91 | # QB: 8
EPS next Quarter (2026-04-30): EPS=2.06 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+6 | Analysts=20
EPS next Year (2027-01-31): EPS=8.60 | Chg7d=+0.001 | Chg30d=+0.001 | Revisions Net=+0 | Growth EPS=+8.2% | Growth Revenue=+12.2%
[Analyst] Revisions Ratio: +0.38 (11 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.9% (Discount Rate 9.7% - Earnings Yield 2.8%)
[Growth] Growth Spread = +4.7% (Analyst 11.5% - Implied 6.9%)
P/E Forward = 21.0526
P/S = 9.6833
P/B = 4.2495
P/EG = 0.8229
Revenue TTM = 3.08b USD
EBIT TTM = 858.9m USD
EBITDA TTM = 908.7m USD
Long Term Debt = 89.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.5m USD (from shortTermDebt, last quarter)
Debt = 89.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.57b USD (from netDebt column, last quarter)
Enterprise Value = 23.28b USD (29.83b + Debt 89.8m - CCE 6.64b)
Interest Coverage Ratio = -3.26 (Ebit TTM 858.9m / Interest Expense TTM -263.2m)
EV/FCF = 17.18x (Enterprise Value 23.28b / FCF TTM 1.35b)
FCF Yield = 5.82% (FCF TTM 1.35b / Enterprise Value 23.28b)
FCF Margin = 43.98% (FCF TTM 1.35b / Revenue TTM 3.08b)
Net Margin = 27.93% (Net Income TTM 860.3m / Revenue TTM 3.08b)
Gross Margin = 75.67% ((Revenue TTM 3.08b - Cost of Revenue TTM 749.5m) / Revenue TTM)
Gross Margin QoQ = 75.41% (prev 75.26%)
Tobins Q-Ratio = 2.88 (Enterprise Value 23.28b / Total Assets 8.10b)
Interest Expense / Debt = 33.69% (Interest Expense 30.2m / Debt 89.8m)
Taxrate = 24.48% (76.6m / 312.8m)
NOPAT = 648.6m (EBIT 858.9m * (1 - 24.48%))
Current Ratio = 7.53 (Total Current Assets 7.11b / Total Current Liabilities 944.9m)
Debt / Equity = 0.01 (Debt 89.8m / totalStockholderEquity, last quarter 7.04b)
Debt / EBITDA = -1.73 (Net Debt -1.57b / EBITDA 908.7m)
Debt / FCF = -1.16 (Net Debt -1.57b / FCF TTM 1.35b)
Total Stockholder Equity = 6.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.83% (Net Income 860.3m / Total Assets 8.10b)
RoE = 13.38% (Net Income TTM 860.3m / Total Stockholder Equity 6.43b)
RoCE = 13.17% (EBIT 858.9m / Capital Employed (Equity 6.43b + L.T.Debt 89.8m))
RoIC = 10.09% (NOPAT 648.6m / Invested Capital 6.43b)
WACC = 9.74% (E(29.83b)/V(29.92b) * Re(9.69%) + D(89.8m)/V(29.92b) * Rd(33.69%) * (1-Tc(0.24)))
Discount Rate = 9.69% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.27%
[DCF] Terminal Value 74.91% ; FCFF base≈1.23b ; Y1≈1.44b ; Y5≈2.17b
[DCF] Fair Price = 176.3 (EV 27.41b - Net Debt -1.57b = Equity 28.98b / Shares 164.4m; r=9.74% [WACC]; 5y FCF grow 17.99% → 2.90% )
EPS Correlation: 90.19 | EPS CAGR: 24.39% | SUE: 1.54 | # QB: 13
Revenue Correlation: 98.71 | Revenue CAGR: 14.67% | SUE: 1.91 | # QB: 8
EPS next Quarter (2026-04-30): EPS=2.06 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+6 | Analysts=20
EPS next Year (2027-01-31): EPS=8.60 | Chg7d=+0.001 | Chg30d=+0.001 | Revisions Net=+0 | Growth EPS=+8.2% | Growth Revenue=+12.2%
[Analyst] Revisions Ratio: +0.38 (11 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.9% (Discount Rate 9.7% - Earnings Yield 2.8%)
[Growth] Growth Spread = +4.7% (Analyst 11.5% - Implied 6.9%)